Ocular side effects of anticancer agents used in the treatment of gynecologic cancers

Area of Science:

• Oncology
• Ophthalmology
• Cancer Therapeutics

Background:

• Gynecologic cancer treatment now includes targeted and immune therapies.
• These novel agents present unique ocular side effects, distinct from traditional chemotherapy.
• Timely identification and management of ocular toxicities are essential to prevent visual impairment.

Purpose of the Study:

• To discuss the management of common ocular toxicities associated with novel anticancer agents for gynecologic cancers.
• To emphasize the importance of clinician awareness and interdisciplinary collaboration for managing these side effects.
• To highlight the need for proactive identification of eye specialists, particularly in underserved areas.

Main Methods:

• Review of common ocular toxicities from targeted and immune therapies in gynecologic oncology.
• Discussion of identification, mitigation, and treatment strategies for ocular adverse events.
• Emphasis on the role of an interdisciplinary team, including ophthalmologists.

Main Results:

• Novel anticancer agents can cause significant ocular side effects.
• Early recognition and intervention are key to managing visual impairment.
• Collaboration with eye specialists is critical for optimal patient care.

Conclusions:

• Clinicians must be prepared to manage ocular toxicities from new gynecologic cancer treatments.
• Interdisciplinary care and timely referral to ophthalmology are vital.
• Proactive planning for specialist access is necessary, especially in resource-limited settings.